<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01929252</url>
  </required_header>
  <id_info>
    <org_study_id>2011/07</org_study_id>
    <nct_id>NCT01929252</nct_id>
  </id_info>
  <brief_title>Postoperative Analgesic Effect Of Dexmedetomidine Administration in Wound Infiltration for Total Abdominal Hysterectomy</brief_title>
  <official_title>Phase 4 Study of Postoperative Analgesic Effect Of Dexmedetomidine Administration in Wound Infiltration For Total Abdominal Hysterectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TC Erciyes University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TC Erciyes University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to investigate the analgesic efficacy of dexmedetomidine
      administration in wound infiltration for total abdominal hysterectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Abdominal hysterectomy is associated with moderate to severe postoperative pain, effective
      analgesia after hysterectomy essential and several techniques are used such as administration
      of opioids, nonsteroidal anti-inflammatory drugs and wound infiltration of local
      anaesthetics. Different local anaesthetics can be used for the wound infiltration
      techniques.Ifiltration of the surgical wound with bupivacaine following outpatient provides
      pain relief in the postoperative period , allows the early discharge from the outpatient
      surgical units.There has been increased interest in administration of analgesic prior to
      surgical injury. Dexmedetomidine is a highly selective alpha-2 adrenergic agonist with
      sedative , anxiolytic, analgesic, sympatholytic and antihypertensive effects.Dexmedetomidine
      has been used intravenously before initiation of anaesthesia and it has shown to provide some
      analgesic effect after surgery but there were some adverse hemodynamic effects. Surgical
      wound administration of dexmedetomidine may be useful to avoid the adverse haemodynamic
      effects of intravenous administration while still providing the postoperative analgesia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analgesic Consumption</measure>
    <time_frame>1 day after surgery</time_frame>
    <description>Pethidine consumption (patient controlled analgesia procedure) was recorded</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale</measure>
    <time_frame>1 day after surgery</time_frame>
    <description>Visual analog scale on rest and movement was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemodynamic Changes</measure>
    <time_frame>During the surgery</time_frame>
    <description>Arterial blood pressure, heart rate, peripheral oxygen saturation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>%0.25 40 ml levobupivacaine and 2 mcg/kg dexmedetomidine administered via wound infiltration just before the incision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levobupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>%0.25 40 ml levobupivacaine administered via wound infiltration prior to incision.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>2mcg.kg-1 dexmedetomidine wound infiltration</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine</intervention_name>
    <description>0.25% levobupivacaine (40ml) wound infiltration</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_label>Levobupivacaine</arm_group_label>
    <other_name>chirocaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-65 yo female

          -  scheduled for elective hysterectomy

          -  no known allergies to drugs

          -  ASA 1=2 patients

        Exclusion Criteria:

          -  history of diabetes

          -  history of chronic pain treatment

          -  pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fatih M. Kurt, Resident</last_name>
    <role>Principal Investigator</role>
    <affiliation>TC Erciyes University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ayse Ulgey, Asst. Prof</last_name>
    <role>Study Director</role>
    <affiliation>TC Erciyes University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Erciyes university hospital</name>
      <address>
        <city>Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2013</study_first_submitted>
  <study_first_submitted_qc>August 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2013</study_first_posted>
  <last_update_submitted>August 22, 2013</last_update_submitted>
  <last_update_submitted_qc>August 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>TC Erciyes University</investigator_affiliation>
    <investigator_full_name>Ayse Ulgey</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>dexmedetomidine</keyword>
  <keyword>wound infiltration</keyword>
  <keyword>postoperative analgesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Levobupivacaine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

